.png){kind=icon}
Neutralizing antibody (nAb) development
Neutralizing antibodies (NAb) occurs when a protein-based biological therapy evokes an adverse immune response. NAbs bind to therapeutic products, diminishing the intended biological function and negatively impacting the therapy efficacy and safety profile in vivo.
Cell-based NAb assays (assessing intracellular signaling events, direct or indirect) are commonly used for NAb detection, as they mimic the in vivo mechanisms more closely than non-cell-based NAb assays.
